Bruce Robinson

Professor Bruce Robinson AC
MD MSc FRACP FAHMS FAICD

Non-Executive Director

Professor Robinson is an endocrinologist. He graduated from the University of Sydney in 1980 and then undertook studies for a Master of Science degree. His further molecular research work was performed at the Brigham and Women’s Hospital and the Children’s Hospital, Harvard Medical School from 1986–1989 and he was awarded a Doctor of Medicine from the University of Sydney in 1990. He has developed and led the Cancer Genetics Laboratory since 1990 and has supervised over 35 doctoral and master’s students working on the genetic basis for tumour formation and gene therapy. He has published over 300 peer-reviewed scientific articles. In 2003, Professor Robinson was awarded the Daiichi Prize by the Asia and Oceania Thyroid Association for this work on the pathogenesis of thyroid cancer.

Until early 2016, Professor Robinson was Associate Dean (International) in the Faculty of Medicine at the University of Sydney and was Head of the Division of Medicine at the Royal North Shore Hospital from 1998–2006. He also served on the Council of the Endocrine Society of Australia from 2001–2005. He is on the editorial board of the international journals Nature, Clinical Practice and Endocrinology and Thyroid. Professor Robinson has a strong interest in furthering relations between Australia and Asia and he is the Founding Chairman of Hoc Mai, the Australia–Vietnam Medical Foundation, which sponsors and supports medical, nursing, allied health and scientific exchanges between Australia and Vietnam. He was awarded the People’s Health Medal by the Vietnamese Government in 2008. He is a Fellow of the Australian Institute of Company Directors.

Professor Robinson was the Chair of the Medicare Benefits Schedule (MBS) Review Taskforce, which considered how services could be aligned with contemporary clinical evidence and improve health outcomes for patients. He is also the Chair of the Council of NHMRC.

Professor Robinson is Co- Head of the Cancer Genetics Laboratory at the Kolling Institute at the Royal North Shore Hospital, and the Dean of Medicine 2006–2016 at the University of Sydney.

Professor Robinson currently holds non-executive director roles with ASX-listed healthcare companies Cochlear Limited and Mayne Pharma Limited.

Professor Robinson was previously a director of QBiotics and was appointed as a director of QBiotics Group on 1 November 2017.